Second Sight Medical (EYES) shares are up more than 20% in pre-market trading today after the company announced positive five-year outcomes data in patients using its Argus II Retinal Prosthesis System. Results from 30 blind patients showed that improved visual function was sustained over five years, including significant improvement in quality of life measures. The device's safety profile was also acceptable.